Multiple Myeloma Articles & Analysis: Older
12 articles found
In addition, persistent activation of NF-κB increases the levels of a number of cytokines that promote cancer growth, such as IL-1β (acute leukemia growth factor), TNF (malignant lymphogranuloma, T-cell lymphoma, and glioma growth factor), and IL-6 (growth factor in multiple myeloma). Two important stages of cancer development are tissue infiltration ...
Carfilzomib, a proteasome inhibitor, is indicated for the treatment of patients with multiple myeloma. Multiple myeloma (multiple myeloma, MM) is a malignant tumor originating from the B cell lineage, characterized by the clonal proliferation of malignant plasma cells in the bone marrow ...
That was until she experienced searing back pain in 2009 and the subsequent collapse of her spine. She was diagnosed with multiple myeloma (MM) and told she might never walk again. Within a few months, Karen transitioned from an outdoor enthusiast to a debilitated “terminal cancer patient” with an estimated two years to live. ...
ACCC just launched updates to the MRD Testing Implementation Roadmap, which aims to help multidisciplinary providers successfully integrate MRD testing into the cancer care continuum for patients with Chronic Lymphocytic Leukemia (CLL) and multiple myeloma, complementing the Roadmap for patients with B-cell acute lymphoblastic leukemia (ALL) which launched ...
This September marks four years since the 2018 Food and Drug Administration clearance for clonoSEQ to detect and monitor minimal residual disease (MRD) in bone marrow from patients with acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). In the years following, researchers have explored the value of using MRD status to guide treatment in blood ...
Only beneficiaries with specific cancer diagnoses and who are receiving systemic chemotherapy treatment (excluding exclusively hormonal therapies) are eligible for EOM, these include: breast cancer, lung cancer, lymphoma, multiple myeloma, small intestine/colorectal, prostate cancer, and chronic leukemia. ...
” In contrast, the researchers observed no effect of the interferon pathway on the sensitivity of leukemia, lymphoma, or multiple myeloma to CAR-T cell therapy. “In fact, we can see different responses of solid and liquid tumors to CAR-T cell therapy, which is very helpful in how we design future ...
Thalidomide and its derivatives for the treatment of multiple myeloma and other conditions have demonstrated the potential of protein degraders, while ARV-471, an estrogen receptor degrader based on the drug development of thalidomide, is targeted at the early stage of breast cancer has continued to show superior performance in clinical trials. ...
The receptors on the surface of CAR-T cells can act as a GPS, looking for special markers on the surface of cancer cells; a variety of CAR-T cell therapies have been approved for the treatment of patients with leukemia, lymphoma and multiple myeloma, but there are currently no CAR-T cell therapies approved for the treatment of solid tumors. ...
Multiple myeloma is an essentially incurable plasma cell cancer with a very poor prognosis for patients; however, in a recent study published in Science Translational Medicine entitled "Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the protein CD98 heavy chain," scientists from Osaka ...
Increased risk of different cancer types in workers employed in petroleum industries and residents living in oil producing communities by Felix Onyije, Bayan Hosseini, Kayo Togawa, Joachim Schüz, and Ann Olsson Considerable health conditions are caused by environmental pollutants, including emissions from petroleum extraction and refining. They are major sources of environmental and ...
Malignant tumors Many malignant tumors can cause elevated serum amylase, the most common are ovarian cancer, lung cancer and multiple myeloma. Ectopic synthesis of tumor tissue is the cause of this phenomenon. ...